https://www.selleckchem.com/products/blu-285.html
6% (95% confidence interval, 44.9%-71.4%), showing the primary endpoint was met (P0.0001). Treatment-related adverse events occurred in two patients (3.4%). Regarding the pharmacokinetics of palonosetron, neither the plasma concentration immediately after administration nor the area under the plasma concentration-time curve from time 0 to infinity differed significantly among the age groups. We demonstrated the efficacy of palonosetron in pediatric patients receiving highly emetogenic chemotherapy or moderately emetogenic chemothera
Like
Comment
Share
